Page last updated: 2024-11-06

acetaminophen sulfate ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acetaminophen sulfate ester: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

paracetamol sulfate : An aryl sulfate that is paracetamol in which the hydroxy group has been replaced by a sulfooxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID83939
CHEMBL ID3544802
CHEBI ID32635
SCHEMBL ID5023104
MeSH IDM0132698

Synonyms (33)

Synonym
acetaminophen sulfate ester
paracetamol sulfate
acetaminophen sulfate
CHEBI:32635 ,
10066-90-7
n-(4-(sulfooxy)phenyl)acetamide
4-acetaminophen sulfate
4-acetamidophenyl hydrogen sulfate
n-acetyl-4-aminophenol sulfate
FT-0661043
(4-acetamidophenyl) hydrogen sulfate
unii-s6002h6j9f
acetamide, n-(4-(sulfooxy)phenyl)-
s6002h6j9f ,
FT-0636624
acetaminophen-4(o)-sulphate
n-acetyl-4-aminophenol sulphate
acetanilide, 4'-hydroxy-, hydrogen sulphate
acetaminophen sulphate
paracetamol sulphate
pcm-s
acetaminophen-4(o)-sulfate
acetanilide, 4'-hydroxy-, hydrogen sulfate
acetaminophen sulphate ester
acetaminophen o-sulfate
SCHEMBL5023104
DTXSID70143433
CHEMBL3544802
4-acetamidophenol sulfate
4-acetamidophenyl hydrogen sulphate
(4-acetamidophenyl) hydrogen sulphate
Q27115027
discontinued see: a161230

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic results obtained with microdialysis sampling were the same as those obtained from blood collection."( In vivo microdialysis sampling for pharmacokinetic investigations.
Lunte, CE; Puckett, DL; Scott, DO; Sorenson, LR; Steele, KL, 1991
)
0.28
" However, a significantly shorter elimination half-life of PCM was observed in the thalassemic subjects (p<0."( A pharmacokinetic study of paracetamol in Thai beta-thalassemia/HbE patients.
Chantharaksri, U; Fucharoen, P; Fucharoen, S; Howard, TA; Morales, NP; Sanvarinda, Y; Sirankapracha, P; Tankanitlert, J; Temsakulphong, A; Ware, RE, 2006
)
0.33
" Our pharmacokinetic data provide additional evidence that plasma PCM-G is higher in thalassemic patients with hyperbilirubinemia, which could be a casual relationship in regulating the UDP-glucuronosyltransferase expression."( A pharmacokinetic study of paracetamol in Thai beta-thalassemia/HbE patients.
Chantharaksri, U; Fucharoen, P; Fucharoen, S; Howard, TA; Morales, NP; Sanvarinda, Y; Sirankapracha, P; Tankanitlert, J; Temsakulphong, A; Ware, RE, 2006
)
0.33
" Paracetamol clearance showed a statistically significant dependence on age group, whereas volume of distribution during elimination and elimination half-life were associated with age group and sex, respectively."( Pharmacokinetics of intravenous paracetamol in elderly patients.
Aantaa, R; Kuusniemi, K; Liukas, A; Neuvonen, PJ; Niemi, M; Olkkola, KT; Virolainen, P, 2011
)
0.37
" The present study evaluated the possiblility of a pharmacokinetic interaction between favipiravir and acetaminophen, in vitro and in vivo."( Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen.
Court, MH; Epstein, CR; Giesing, D; Greenblatt, DJ; Harmatz, JS; Kadota, T; Kurosaki, C; Nakagawa, Y; Nakamura, T; Zhao, Y, 2015
)
0.42
" In human volunteers, both acute (1 day) and extended (6 days) administration of favipiravir slightly but significantly increased (by about 20 %) systemic exposure to acetaminophen (total AUC), whereas Cmax was not significantly changed."( Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen.
Court, MH; Epstein, CR; Giesing, D; Greenblatt, DJ; Harmatz, JS; Kadota, T; Kurosaki, C; Nakagawa, Y; Nakamura, T; Zhao, Y, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
"1 The rate of absorption of oral paracetamol depends on the rate of gastric emptying and is usually rapid and complete."( Kinetics and metabolism of paracetamol and phenacetin.
Prescott, LF, 1980
)
0.26
" The apparent AUC for paracetamol in the camel following intramuscular administration was larger than that following intravenous administration, however, when the bioavailability (F) was determined, with correction for altered half-life, within the animal and between study phases it was 71 +/- 17% in goats and 105 +/- 26% in camels."( Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats.
Ali, BH; Bashir, AK; Cheng, Z; el Hadrami, G; McKellar, QA, 1996
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Rabbits were dosed intravenously with acetaminophen (NAPA, 30 mg/kg)."( A method for the preparation of calibration curves for acetaminophen glucuronide and acetaminophen sulfate in rabbit urine without use of authentic compounds in high-performance liquid chromatography.
Baba, S; Nakamura, J; Nakamura, T; Sasaki, H; Shibasaki, J, 1987
)
0.27
" It is not clear why regular dosing with paracetamol in haemodialysis patients did not cause the accumulation of paracetamol glucuronide or sulphate as predicted."( The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis.
Martin, U; Prescott, LF; Temple, RM; Winney, RJ, 1993
)
0.29
" Male Sprague-Dawley rats were each dosed with either phenacetin or phenacetin-C2H3 at 50 mg kg-1."( NMR spectroscopic studies on the metabolism and futile deacetylation of phenacetin in the rat.
Caddick, S; Farrant, RD; Lindon, JC; Nicholls, AW; Nicholson, JK; Wilson, ID, 1997
)
0.3
"To investigate the pharmacokinetics, metabolism, and dose-response relation of a single rectal dose of paracetamol in preterm infants in two different age groups."( Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates.
Anand, KJ; Deinum, JT; Kuizenga, AJ; Okken, A; Quak, JM; Tibboel, D; van Dam, JG; van Lingen, RA, 1999
)
0.3
"5, 2, 3, 4, 5, 7, and 9 h after dosing for determination of the plasma levels of PCM and its metabolites by high-performance liquid chromatography."( A pharmacokinetic study of paracetamol in Thai beta-thalassemia/HbE patients.
Chantharaksri, U; Fucharoen, P; Fucharoen, S; Howard, TA; Morales, NP; Sanvarinda, Y; Sirankapracha, P; Tankanitlert, J; Temsakulphong, A; Ware, RE, 2006
)
0.33
" The value for area under the concentration-time curve over the 6h dosing interval of venous plasma (45."( Investigating paracetamol pharmacokinetics using venous and capillary blood and saliva sampling.
McLachlan, AJ; Rittau, AM, 2012
)
0.38
" This study investigates paracetamol clearance in neonates and infants after single and multiple dosing using a population modelling approach."( Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants.
Allegaert, K; Danhof, M; de Hoon, J; Knibbe, CA; Krekels, EH; Tibboel, D; van Ham, S, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aryl sulfate
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase II - Conjugation of compounds73122
Cytosolic sulfonation of small molecules1747
Acetaminophen Metabolism Pathway3016
Drug ADME6387
APAP ADME1730

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1292831Renal clearance in healthy human assessed as paracetamol sulfate level at 20 mg/kg1980British journal of clinical pharmacology, Oct, Volume: 10 Suppl 2Kinetics and metabolism of paracetamol and phenacetin.
AID1292899Cmax in human adults at 20 mg/kg1980British journal of clinical pharmacology, Oct, Volume: 10 Suppl 2Kinetics and metabolism of paracetamol and phenacetin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (16.42)18.7374
1990's19 (28.36)18.2507
2000's20 (29.85)29.6817
2010's15 (22.39)24.3611
2020's2 (2.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.24 (24.57)
Research Supply Index4.39 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (14.29%)5.53%
Reviews1 (1.43%)6.00%
Case Studies2 (2.86%)4.05%
Observational1 (1.43%)0.25%
Other56 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]